Bone Marrow Transplant
|Closed||Multiple Myeloma (MM)||Phase II||
RATIONALE: Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with vorinostat after an autologous stem cell transplant may stop the growth of any cancer cells that remain after transplant.
PURPOSE: This phase II trial is studying the side effects of giving bortezomib together with vorinostat and to see how well it works in treating patients with multiple myeloma who have undergone autologous stem cell transplant.
|Ages Eligible for Study:||18 Years and older|
|Genders Eligible for Study:||Both|
|Accepts Healthy Volunteers:||No|
Diagnosis of multiple myeloma
- Any disease stage allowed
- Must have undergone autologous peripheral blood stem cell transplantation that included high-dose melphalan (≥ 140 mg/m²) within the past 30-120 days
- No symptomatic ascites or pleural effusions
- No history of CNS disease
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.